TY - JOUR AU - Adès, L. AU - Itzykson, R. AU - Fenaux, P. PY - 2014 DA - 2014// TI - Myelodysplastic syndromes JO - Lancet. VL - 383 UR - https://doi.org/10.1016/S0140-6736(13)61901-7 DO - 10.1016/S0140-6736(13)61901-7 ID - Adès2014 ER - TY - BOOK PY - 2015 DA - 2015// TI - Cancer Facts & Figures 2015 PB - American Cancer Society CY - Atlanta ID - ref2 ER - TY - JOUR AU - Cogle, C. R. PY - 2015 DA - 2015// TI - Incidence and burden of the myelodysplastic syndromes JO - Curr Hematol Malig Rep VL - 10 UR - https://doi.org/10.1007/s11899-015-0269-y DO - 10.1007/s11899-015-0269-y ID - Cogle2015 ER - TY - JOUR AU - Fenaux, P. AU - Mufti, G. J. AU - Hellstrom-Lindberg, E. PY - 2009 DA - 2009// TI - Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study JO - Lancet Oncol VL - 10 UR - https://doi.org/10.1016/S1470-2045(09)70003-8 DO - 10.1016/S1470-2045(09)70003-8 ID - Fenaux2009 ER - TY - JOUR AU - Fenaux, P. AU - Ades, L. PY - 2013 DA - 2013// TI - How we treat lower-risk myelodysplastic syndromes JO - Blood. VL - 121 UR - https://doi.org/10.1182/blood-2013-02-453068 DO - 10.1182/blood-2013-02-453068 ID - Fenaux2013 ER - TY - JOUR AU - Fenaux, P. AU - Haase, D. AU - Sanz, G. F. PY - 2014 DA - 2014// TI - Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up JO - Annals of Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu180 DO - 10.1093/annonc/mdu180 ID - Fenaux2014 ER - TY - JOUR AU - Cogle, C. R. AU - Craig, B. M. AU - Rollison, D. E. PY - 2011 DA - 2011// TI - Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries JO - Blood. VL - 117 UR - https://doi.org/10.1182/blood-2011-02-337964 DO - 10.1182/blood-2011-02-337964 ID - Cogle2011 ER - TY - JOUR AU - Greenberg, P. L. AU - Tuechler, H. AU - Schanz, J. PY - 2012 DA - 2012// TI - Revised international prognostic scoring system for myelodysplastic syndromes JO - Blood. VL - 120 UR - https://doi.org/10.1182/blood-2012-03-420489 DO - 10.1182/blood-2012-03-420489 ID - Greenberg2012 ER - TY - JOUR AU - Greenberg, P. AU - Cox, C. AU - LeBeau, M. M. PY - 1997 DA - 1997// TI - International scoring system for evaluating prognosis in myelodysplastic syndromes JO - Blood. VL - 89 UR - https://doi.org/10.1182/blood.V89.6.2079 DO - 10.1182/blood.V89.6.2079 ID - Greenberg1997 ER - TY - JOUR AU - Garcia-Manero, G. PY - 2014 DA - 2014// TI - Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management JO - Am J Hematol VL - 89 UR - https://doi.org/10.1002/ajh.23642 DO - 10.1002/ajh.23642 ID - Garcia-Manero2014 ER - TY - JOUR AU - Lübbert, M. AU - Suciu, S. AU - Baila, L. PY - 2011 DA - 2011// TI - Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.30.9245 DO - 10.1200/JCO.2010.30.9245 ID - Lübbert2011 ER - TY - JOUR AU - Götze, K. AU - Platzbecker, U. AU - Giagounidis, A. PY - 2010 DA - 2010// TI - Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group JO - Ann Hematol VL - 89 UR - https://doi.org/10.1007/s00277-010-1015-0 DO - 10.1007/s00277-010-1015-0 ID - Götze2010 ER - TY - STD TI - Gardin C, Thépot S, Beyne-Rauzy O, et al. Results of a phase II trial of azacitidine (AZA) with or without epoetin beta (EPO) in lower-risk MDS. J Clin Oncol. 2012;30(Suppl):6523. ID - ref13 ER - TY - JOUR AU - Fenaux, P. AU - Giagounidis, A. AU - Selleslag, D. PY - 2011 DA - 2011// TI - A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low−/intermediate-1-risk myelodysplastic syndromes with del5q JO - Blood. VL - 118 UR - https://doi.org/10.1182/blood-2011-01-330126 DO - 10.1182/blood-2011-01-330126 ID - Fenaux2011 ER - TY - JOUR AU - Hellstrom-Lindberg, E. AU - Gulbrandsen, N. AU - Lindberg, G. PY - 2003 DA - 2003// TI - A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life JO - Br J Haematol VL - 120 UR - https://doi.org/10.1046/j.1365-2141.2003.04153.x DO - 10.1046/j.1365-2141.2003.04153.x ID - Hellstrom-Lindberg2003 ER - TY - STD TI - Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review. Bethesda: National Cancer Institute; 1975–2013. ID - ref16 ER - TY - JOUR AU - Jiang, Y. AU - Dunbar, A. AU - Gondek, L. P. PY - 2009 DA - 2009// TI - Aberrant DNA methylation is a dominant mechanism in MDS progression to AML JO - Blood. VL - 113 UR - https://doi.org/10.1182/blood-2008-06-163246 DO - 10.1182/blood-2008-06-163246 ID - Jiang2009 ER - TY - JOUR AU - List, A. AU - Dewald, G. AU - Bennett, J. PY - 2006 DA - 2006// TI - Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa061292 DO - 10.1056/NEJMoa061292 ID - List2006 ER - TY - JOUR AU - Lyons, R. M. AU - Cosgriff, T. M. AU - Modi, S. S. PY - 2009 DA - 2009// TI - Hematologic response to 3 alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.17.1058 DO - 10.1200/JCO.2008.17.1058 ID - Lyons2009 ER - TY - JOUR AU - Oliva, E. N. AU - Cuzzola, M. AU - Aloe Spiriti, M. A. PY - 2013 DA - 2013// TI - Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study JO - Ann Hematol VL - 92 UR - https://doi.org/10.1007/s00277-012-1569-0 DO - 10.1007/s00277-012-1569-0 ID - Oliva2013 ER - TY - JOUR AU - Raza, A. AU - Reeves, J. A. AU - Feldman, E. J. PY - 2008 DA - 2008// TI - Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q JO - Blood. VL - 111 UR - https://doi.org/10.1182/blood-2007-01-068833 DO - 10.1182/blood-2007-01-068833 ID - Raza2008 ER - TY - JOUR AU - Kantarjian, H. AU - Issa, J. P. AU - Rosenfeld, C. S. PY - 2006 DA - 2006// TI - Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study JO - Cancer. VL - 106 UR - https://doi.org/10.1002/cncr.21792 DO - 10.1002/cncr.21792 ID - Kantarjian2006 ER - TY - JOUR AU - Crawford, J. AU - Cella, D. AU - Cleeland, C. S. PY - 2002 DA - 2002// TI - Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy JO - Cancer. VL - 95 UR - https://doi.org/10.1002/cncr.10763 DO - 10.1002/cncr.10763 ID - Crawford2002 ER - TY - JOUR AU - Santini, V. AU - Almeida, A. AU - Giagounidis, A. PY - 2014 DA - 2014// TI - Efficacy and safety of lenalidomide (len) versus placebo (pbo) in RBC-transfusion dependent (td) patients (pts) with IPSS low/intermediate (Int-1)-risk myelodysplastic syndromes (MDS) without del (5q) and unresponsive or refractory to erythropoiesis-stimulating agents (ESAs): results from a randomized phase 3 study (CC-5013-MDS-005) JO - Blood. VL - 124 UR - https://doi.org/10.1182/blood.V124.21.409.409 DO - 10.1182/blood.V124.21.409.409 ID - Santini2014 ER - TY - JOUR AU - Kelaidi, C. AU - Park, S. AU - Sapena, R. PY - 2013 DA - 2013// TI - Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents JO - Leukemia. VL - 27 UR - https://doi.org/10.1038/leu.2013.16 DO - 10.1038/leu.2013.16 ID - Kelaidi2013 ER - TY - JOUR AU - Sekeres, M. A. AU - Cutler, C. PY - 2014 DA - 2014// TI - How we treat higher-risk myelodysplastic syndromes JO - Blood. VL - 123 UR - https://doi.org/10.1182/blood-2013-08-496935 DO - 10.1182/blood-2013-08-496935 ID - Sekeres2014 ER - TY - JOUR AU - Shen, L. AU - Kantarjian, H. AU - Guo, Y. PY - 2010 DA - 2010// TI - DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.23.4781 DO - 10.1200/JCO.2009.23.4781 ID - Shen2010 ER - TY - JOUR AU - Silverman, L. R. AU - Demakos, E. P. AU - Peterson, B. L. PY - 2002 DA - 2002// TI - Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.04.117 DO - 10.1200/JCO.2002.04.117 ID - Silverman2002 ER - TY - JOUR AU - Garcia-Manero, G. AU - Gore, S. D. AU - Cogle, C. PY - 2011 DA - 2011// TI - Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.34.4226 DO - 10.1200/JCO.2010.34.4226 ID - Garcia-Manero2011 ER - TY - JOUR AU - Garcia-Manero, G. AU - Fenaux, P. PY - 2011 DA - 2011// TI - Hypomethylating agents and other novel strategies in myelodysplastic syndromes JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.31.0854 DO - 10.1200/JCO.2010.31.0854 ID - Garcia-Manero2011 ER - TY - JOUR AU - Garcia-Manero, G. AU - Jabbour, E. AU - Borthakur, G. PY - 2013 DA - 2013// TI - Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.6823 DO - 10.1200/JCO.2012.44.6823 ID - Garcia-Manero2013 ER - TY - JOUR AU - Loiseau, C. AU - Ali, A. AU - Itzykson, R. PY - 2015 DA - 2015// TI - New therapeutic approaches in myelodysplastic syndromes: hypomethylating agents and lenalidomide JO - Exp Hematol VL - 43 UR - https://doi.org/10.1016/j.exphem.2015.05.014 DO - 10.1016/j.exphem.2015.05.014 ID - Loiseau2015 ER - TY - JOUR AU - Chen, X. AU - Eksioglu, E. A. AU - Zhou, J. PY - 2013 DA - 2013// TI - Induction of myelodysplasia by myeloid-derived suppressor cells JO - J Clin Invest VL - 123 UR - https://doi.org/10.1172/JCI67580 DO - 10.1172/JCI67580 ID - Chen2013 ER - TY - JOUR AU - Ganan-Gomez, I. AU - Wei, Y. AU - Starczynowski, D. T. PY - 2015 DA - 2015// TI - Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes JO - Leukemia. VL - 29 UR - https://doi.org/10.1038/leu.2015.69 DO - 10.1038/leu.2015.69 ID - Ganan-Gomez2015 ER - TY - JOUR AU - Eksioglu, E. A. AU - Chen, X. AU - Heider, K. -. H. PY - 2017 DA - 2017// TI - Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858 JO - Leukemia. VL - 31 UR - https://doi.org/10.1038/leu.2017.21 DO - 10.1038/leu.2017.21 ID - Eksioglu2017 ER - TY - JOUR AU - Hoechst, B. AU - Voigtlaender, T. AU - Ormandy, L. PY - 2009 DA - 2009// TI - Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor JO - Hepatology. VL - 50 UR - https://doi.org/10.1002/hep.23054 DO - 10.1002/hep.23054 ID - Hoechst2009 ER - TY - STD TI - Riether C, Schürch CM, Flury C, et al. Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. Sci Transl Med. 2015;7(298):298ra119. ID - ref37 ER - TY - JOUR AU - Gleason, M. K. AU - Ross, J. A. AU - Warlick, E. D. PY - 2014 DA - 2014// TI - CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets JO - Blood. VL - 123 UR - https://doi.org/10.1182/blood-2013-10-533398 DO - 10.1182/blood-2013-10-533398 ID - Gleason2014 ER - TY - JOUR AU - Li, L. AU - Tao, J. AU - Fu, R. PY - 2014 DA - 2014// TI - Increased CD34+C38-CD123+ cells in myelodysplastic syndrome displaying malignant features similar to those in AML JO - Int J Hematol VL - 100 UR - https://doi.org/10.1007/s12185-014-1590-2 DO - 10.1007/s12185-014-1590-2 ID - Li2014 ER - TY - JOUR AU - Sun, B. Q. AU - Woodcock, J. M. AU - Rapoport, A. PY - 1996 DA - 1996// TI - Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (Il-3) receptor alpha-chain and functions as a specific Il-3 receptor antagonist JO - Blood VL - 87 UR - https://doi.org/10.1182/blood.V87.1.83.83 DO - 10.1182/blood.V87.1.83.83 ID - Sun1996 ER - TY - JOUR AU - Yue, L. Z. AU - Fu, R. AU - Wang, H. Q. PY - 2010 DA - 2010// TI - Expression of CD123 and CD114 on the bone marrow cells of patients with myelodysplastic syndrome JO - Chin Med J (Engl) VL - 123 ID - Yue2010 ER - TY - JOUR AU - Nievergall, E. AU - Ramshaw, H. S. AU - Yong, A. S. M. PY - 2014 DA - 2014// TI - Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells JO - Blood. VL - 123 UR - https://doi.org/10.1182/blood-2012-12-475194 DO - 10.1182/blood-2012-12-475194 ID - Nievergall2014 ER - TY - JOUR AU - He, S. Z. AU - Busfield, S. AU - Ritchie, D. S. PY - 2014 DA - 2014// TI - A phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia JO - Leukemia Lymphoma VL - 56 UR - https://doi.org/10.3109/10428194.2014.956316 DO - 10.3109/10428194.2014.956316 ID - He2014 ER - TY - JOUR AU - Ge, H. AU - Mu, L. AU - Jin, L. PY - 2017 DA - 2017// TI - Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM JO - Int J Cancer VL - 141 UR - https://doi.org/10.1002/ijc.30830 DO - 10.1002/ijc.30830 ID - Ge2017 ER - TY - JOUR AU - Gustafson, M. P. AU - Lin, Y. AU - Maas, M. L. PY - 2015 DA - 2015// TI - Identification and analysis of non-overlapping myeloid immunophenotypes in humans JO - Plos One VL - 10 UR - https://doi.org/10.1371/journal.pone.0121546 DO - 10.1371/journal.pone.0121546 ID - Gustafson2015 ER - TY - STD TI - Krejcik J, Syed K, Sasser AK, et al. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–94. ID - ref46 ER - TY - JOUR AU - Lazar, G. A. AU - Dang, W. AU - Karki, S. PY - 2006 DA - 2006// TI - Engineered antibody Fc variants with enhanced effector function JO - Proc Natl Acad Sci U S A VL - 103 UR - https://doi.org/10.1073/pnas.0508123103 DO - 10.1073/pnas.0508123103 ID - Lazar2006 ER - TY - JOUR AU - Busfield, S. J. AU - Biondo, M. AU - Wong, M. PY - 2014 DA - 2014// TI - Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC JO - Leukemia. VL - 28 UR - https://doi.org/10.1038/leu.2014.128 DO - 10.1038/leu.2014.128 ID - Busfield2014 ER - TY - JOUR AU - Broughton, S. E. AU - Hercus, T. R. AU - Hardy, M. P. PY - 2014 DA - 2014// TI - Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody JO - Cell Rep VL - 8 UR - https://doi.org/10.1016/j.celrep.2014.06.038 DO - 10.1016/j.celrep.2014.06.038 ID - Broughton2014 ER -